DiagnoCure gets DxS' Scorpions for colorectal cancer test:
This article was originally published in Clinica
Manchester, UK-based molecular diagnostics company DxS has licensed its Scorpions technology to Canada's DiagnoCure for use in the latter's colorectal cancer tests. Financial terms of the agreement were not disclosed. DxS' technology is said to be ideal for cancer tests as it employs probes that are highly sensitive and specific, thereby improving productivity and lowering the costs of processing the tests. DiagnoCure will use the technology to detect GC-C (guanylyl cyclase c), a gene that appears normally in cells lining the intestinal tract, but is found on the outside of the intestine when colorectal cancer has metastasised.